Philippines Pharmaceuticals & Healthcare Report Q1 2015 - New Market Report

Our outlook for the Philippines' pharmaceutical sector remains bullish, driven by an increasing population and high burden of disease profile. Generic medicines will continue to account for an increasing share of pharmaceutical sales in the Philippines, galvanised by expanding government provision of healthcare as well as improvements in generic drug distribution. This provides strong growth opportunities for generic drug manufacturers in an emerging market where economic growth will be sustained by robust private consumption. Howeve r, current access to medicines and treatment will continue to negatively impact the wider market.

Headline Expenditure Projections

* Pharmaceuticals: PHP140.20bn (USD3.25bn) in 2013, rising to PHP145.05bn (USD3.26bn) in 2014; +3.5% in local currency terms and +0.4% in US dollar terms.
* Healthcare: PHP545.09bn (USD12.62bn) in 2013, rising to PHP612.04bn (USD13.75bn) in 2014; +12.3% in local currency terms and +9.0% in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/924248_philippines_pharmaceuticals_healthcare_report_q1.aspx?afid=301

Risk/Reward Index : Out of the 19 pharmaceutical markets assessed in Asia Pacific, the Philippines remain in 14th place (scoring 45.3 out of 100), trailing the regional average in most metrics. In Q115, Japan is ranked as the most attractive market in the Asia Pacific region (scoring 78.1 out of 100), followed by South Korea (68.6). Compared with its peers, the Philippines' RRI score is dragged down by industry characteristics such as policy enforcement.

Key Trends And Developments

November

* Healthcare problems, such as accessibility, availability and affordability, will persist nationwide beyond 2015 even if the Philippines achieves its health-related Millennium Development Goal (MDG) commitments by 2015, according to state-owned Philippine Institute for Development Studies (PIDS). According to PIDS Senior Research Fellow Celia Reyes, this is because Filipinos living in Luzon still receive better access to health services and facilities than Filipinos in the Visayas and Mindanao....

The Philippines Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Philippines Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Philippine pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Philippines to test other views - a key input for successful budgeting and strategic business planning in the Philippine pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Peru Pharmaceuticals & Healthcare Report Q1 2015
- Lebanon Pharmaceuticals & Healthcare Report Q1 2015
- Turkey Pharmaceuticals & Healthcare Report Q1 2015
- India Pharmaceuticals & Healthcare Report Q1 2015
- Slovenia Pharmaceuticals & Healthcare Report Q1 2015